Analytical Data
-
Gene name
CLEC11A
- Application
-
Alternative Names
SCGF; P47; LSLCL; CLECSF3; Stem Cell Growth Factor; Lymphocyte Secreted C-Type Lectin; C-type lectin superfamily member 3
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y240
-
Expression Region
Ala22~Phe323
-
Molecular Weight
64kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CLEC11A (C-type lectin domain family 11 member A) is a protein that has garnered significant attention in recent years due to its potential roles in various biological processes and diseases. Initially identified as a protein involved in the regulation of immune responses, CLEC11A has been implicated in the differentiation and maturation of myeloid cells, influencing both innate and adaptive immunity. Research has shown that CLEC11A can modulate the activity of dendritic cells and macrophages, which are crucial for initiating immune responses. Furthermore, its expression has been associated with certain pathological conditions, including cancer, where it may affect tumor in stromal interactions and immune evasion mechanisms. Given its multifunctional nature, the recombinant expression of CLEC11A presents an opportunity for further investigations into its functional roles. Studies focusing on CLEC11A recombinant protein aim to elucidate its binding mechanisms, signaling pathways, and interactions with other cellular components. By understanding the structural and functional properties of CLEC11A, researchers hope to identify its potential as a therapeutic target or biomarker in diseases such as cancer and autoimmune disorders. The ongoing research into CLEC11A reinforces the significance of this protein in both basic and applied biomedical sciences, highlighting its potential implications in improving disease management and treatment strategies.
